← All trials
NCT05788601
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2023
- Primary completion
- Feb 15, 2024
- Completion date
- Aug 15, 2024
- First posted
- Mar 29, 2023
- Last posted
- Oct 16, 2023
- Enrollment
- 54
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- Zealand PharmaCollaborator
- University of CopenhagenOverall official - principal investigator
- University of CopenhagenReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.